Drugs / Gamimune N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01556347 | Jul 2012 → May 2016 | — | Providence Health & Services | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamimune N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01556347 ↗ |
| Modality | Protein / enzyme biologic | “The anti-inflammatory properties of IVIG can now be attributed to Fc sialylation of IgG” NCT01556347 ↗ |
| Route | Intravenous | “intravenous immunoglobulin, IVIG” NCT01556347 ↗ |